Company Overview and News
AmerisourceBergen Corporation’s (ABC - Free Report) third-quarter fiscal 2018 results are scheduled for release on Aug 2, before market opens. While the company’s core Pharmaceutical Distribution unit is likely to drive growth, stiff competition is likely to mar prospects.
ABC TFX RAD CAH PKI EW
Edwards Lifesciences Corporation (EW - Free Report) is slated to report second-quarter 2018 results, after the market closes on Jul 26. Last quarter, the company’s earnings beat the Zacks Consensus Estimate by 10.9%. Moreover, Edwards Lifesciences has delivered positive earnings surprises in three of the trailing four quarters, the average beat being 8.9%. Let's see how things are shaping up prior to this announcement.
ALGN BAX HSIC EW
Becton, Dickinson and Company’s (BDX - Free Report) , popularly known as BD, third-quarter fiscal 2018 results are scheduled to release on Aug 2, before the market opens. While the results are likely to show steady growth in the core BD Medical segment, decline in other segments are apprehended.
TFX PKI EW
athenahealth Inc. (ATHN - Free Report) is scheduled to report second-quarter 2018 results on Jul 30, after market close. While the company’s core Business Services segment is likely to drive growth, a decline in Implementation and Other segment might offset it partially.
TFX ATHN PKI EW
Edwards Lifesciences Corporation (EW - Free Report) has been gaining investor confidence on consistently positive results. Over the past six months, the stock has gained 21.8% against its industry’s 17.8% decline. Also, the company has outperformed the S&P 500’s 0.7% increase.
ALGN SYK SAM GHDX EW
The iShares Morningstar Mid-Cap Growth ETF (JKH - Free Report) was launched on 06/28/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Mid Cap Growth segment of the US equity market.
NOW MORN RHT EW
With a market capitalization of approximately $2.54 billion, Merit Medical Systems, Inc.’s (MMSI - Free Report) acquisition-driven strategy is expected to boost growth through the expansion of product offerings in all business segments. Favorable prospects in the HeRO product line also bodes well.
TRUMY TRUMF MMSI BSX SYK HFC CAH ABMD GHDX EW
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
The global medical device industry has demonstrated strong and sustainable growth in the recent past. Banking on an aging population, increasing incidence of chronic and lifestyle diseases, increasing adoption of artificial intelligence (AI) and big-data applications, upbeat consumer sentiment and increased business investments, this sector appears to be in the pink of health.
STE VAR BSX JNJ HAE CSX CI BAX CVS YY EW
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to EW / Edwards Lifesciences Corp. on message board site Silicon Investor.
as of ET